Genvoya

The first quarter earnings of Gilead Sciences, Inc. (NASDAQ: GILD) may miss the Street view, but promising Hep C Rx trends drive a positive outlook, according to a note from Baird. Analyst Brian Skorney said, "Our estimate for pro forma fully diluted EPS is $2.92 versus consensus at $3.12. We think...